To collect clinical response data with the use of ertapenem in approved indications.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Signs and symptoms of infection on days 3, 4, 7 and 14 during treatment
Safety and Tolerability
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.